A Moraxella bovis pili vaccine produced by recombinant DNA technology for the prevention of infectious bovine keratoconjunctivitis.
Pili (fimbriae) were prepared from Moraxella bovis strain Dalton 2d (Dal2d) and from a derivative of Pseudomonas aeruginosa K/2PfS that contained a plasmid-borne Dal2d pilin gene and produced pili having serogroup-specific identity to Dal2d. Nine calves were vaccinated with two doses each of 30 micrograms authentic M. bovis Dal2d pili in oil adjuvant and 10 calves were vaccinated with a similar dose of P. aeruginosa-derived Dal2d pili in the same formulation. All 19 calves and 10 non-vaccinated controls were challenged by instillation of 1 x 10(9) virulent M. bovis Dal2d cells into both conjunctival sacs 19 days after the second vaccine dose. The serological response to vaccination and the degree of protection against experimentally induced infectious bovine keratoconjunctivitis (IBK) were assessed. None of the nine calves vaccinated with authentic M. bovis Dal2d pili developed IBK while two of those vaccinated with P. aeruginosa-derived Dal2d pili developed lesions which accounted for a mean group lesion score of 0.3. In contrast, 9 of the 10 non-vaccinated calves developed IBK lesions, the majority of which were progressive, required early treatment and accounted for a mean group lesion score of 1.5. These results demonstrate the potential of a relatively low dose of pili produced by recombinant DNA technology for development of an effective vaccine against IBK.
Lepper
A W
AW
CSIRO Division of Animal Health, Animal Health Research Laboratory, Parkville, Vic., Australia.
Elleman
T C
TC
Hoyne
P A
PA
Lehrbach
P R
PR
Atwell
J L
JL
Schwartzkoff
C L
CL
Egerton
J R
JR
Tennent
J M
JM
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000942:Antigens, Bacterial / Q000276:immunology / Q000302:isolation & purification; D001428:Bacterial Vaccines / Q000276:immunology; D015153:Blotting, Western / Q000662:veterinary; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D005260:Female; D010861:Fimbriae, Bacterial / Q000276:immunology; D007639:Keratoconjunctivitis, Infectious / Q000517:prevention & control*; D008297:Male; D016955:Moraxella bovis / Q000276:immunology* / Q000648:ultrastructure; D016870:Neisseriaceae Infections / Q000517:prevention & control / Q000662:veterinary*; D011550:Pseudomonas aeruginosa / Q000276:immunology / Q000648:ultrastructure; D014611:Vaccination / Q000662:veterinary; D014614:Vaccines, Synthetic / Q000276:immunology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D014614:Vaccines, Synthetic